Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0276640 (
TEM
)
20,729
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Enterobacter aerogenes clinical isolate
LOR
was resistant to penicillins and ceftazidime but susceptible to cefuroxime, cephalothin, cefoxitin, cefotaxime, ceftriaxone, and cefepime. PCR and cloning experiments from this strain identified a novel
TEM
-type beta-lactamase (
TEM
-121) differing by five amino acid substitutions from beta-lactamase
TEM
-2 (Glu104Lys, Arg164Ser, Ala237Thr, Glu240Lys, and Arg244Ser) and by only one amino acid change from the extended-spectrum beta-lactamase (ESBL)
TEM
-24 (Arg244Ser), with the last substitution also being identified in the inhibitor-resistant beta-lactamase IRT-2. Kinetic parameters indicated that
TEM
-121 hydrolyzed ceftazidime and aztreonam (like
TEM
-24) and was inhibited weakly by clavulanic acid and strongly by tazobactam. Thus,
TEM
-121 is a novel complex mutant
TEM
beta-lactamase (CMT-4) combining the kinetic properties of an ESBL and an inhibitor-resistant
TEM
enzyme.
...
PMID:TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes. 1556 21
